非結核性抗酸菌（NTM）：機会の評価と予測

当レポートでは、非結核性抗酸菌（NTM）の主要7市場（米国、欧州5ヶ国、日本）について調査し、疾患の概要、市場の収益の予測、パイプラインの分析、現在と将来の競合の分析などを提供しています。

目次

第1章 序文

• コンテンツ
• 略語
• 関連レポート

第2章 エグゼクティブサマリー

第3章 疾患の概要

• NTMの概要
• NTM市場のSWOT分析
• NTMの分類
• NTMの危険因子

第4章 疫学

• NTMの発病者数、N、男女（2023年～2033年）
• NTMの有病者数、男女、N（2023年～2033年）
• NTM、PNTM、DNTMの発病者数、男女、N（2023年）
• NTM、PNTM、DNTMの有病者数、男女、N（2023年）
• NTM、PNTM、DNTMの発病者数の情報源と調査手法
• NTM、PNTM、DNTMの有病者数の情報源と調査手法
• NTMの発病者数/有病者数の情報源と調査手法
• PNTMの発病者数/有病者数の情報源と調査手法
• DNTMの発病者数/有病者数の情報源と調査手法

第5章 現在の治療オプション

• PNTM診断パラダイム
• 治療パラダイム
• 現在の治療オプション

第6章 アンメットニーズと機会

• NTMにおけるアンメットニーズ
• 有効性が向上した新たな治療オプション
• 診断方法の改良
• 臨床試験の改良

第7章 研究開発戦略

• NTMにおける臨床試験デザインの動向
• NTMにおける取引決定の動向

第8章 パイプラインの評価

• NTMのパイプラインの概要
• NTM向けの後期パイプライン製品
• NTMの臨床試験（フェーズII/III）の概要

第9章 市場見通し

• NTM市場の予測
• PNTM市場の予測
• DNTM市場の予測
• 市場の促進要因と障壁

第10章 付録

第11章 お問い合わせ

The report provides an assessment of the NTM therapeutics market including disease overview, epidemiology, current treatment options, unmet needs and opportunities, R&D strategies, pipeline assessment, and market outlook.

NTM refers to infection with a group of bacteria within the Mycobacterium genus, which excludes Mycobacterium tuberculosis (tuberculosis) and Mycobacterium leprae (leprosy). NTM infections are noncontagious, opportunistic infections that cause a wide range of clinical disease in patients with pre-existing health conditions or compromised immune systems. ). In terms of global burden, NTM lung disease is relatively uncommon. It is suggested that host defense mechanisms in most healthy individuals are sufficient to prevent or suppress NTM infection. Patients who develop NTM lung disease likely have susceptibility factors such as pre-existing comorbidities that make them vulnerable to these infections.

Key Highlights

• Report deliverables include a Pdf report and an Excel-based forecast model
• Forecast includes the 7 major markets (7MM)
• Forecast covers the period 2023-2033

Scope

• Overview of NTM, including classification, epidemiology, diagnostic and treatment paradigms.
• Annualized NTM therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
• Key topics covered include assessment of marketed therapies and pipeline agents, unmet needs, pipeline assessment and market outlook for the US, 5EU, and Japan over the 10-year forecast period.
• Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
• Analysis of the current and future market competition in the 7MM NTM therapeutics market. Insightful review of the key industry drivers and barriers.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipelines.
• Develop business strategies by understanding the trends shaping and driving the 7MM NTM therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the NTM therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Table of Contents

1. Preface

• 1.1. Contents
• 1.2. Abbreviations
• 1.3. Related Reports

2. Executive Summary

3. Disease Overview

• 3.1. Overview of NTM
• 3.2. NTM Market SWOT Analysis
• 3.3. Classification of NTM
• 3.4. NTM Risk Factors

4. Epidemiology

• 4.1. Diagnosed Incident Cases NTM, N, Both Sexes, 2023-33
• 4.2. Diagnosed Prevalent Cases of NTM, Both Sexes, N, 2023-33
• 4.3. Diagnosed Incident Cases of NTM, PNTM, and DNTM, Both Sexes, N, 2023
• 4.4. Diagnosed Prevalent Cases of NTM, PNTM, and DNTM, Both Sexes, N, 2023
• 4.5. Sources and Methodology for Diagnosed Incident Cases of NTM, PNTM, and DNTM
• 4.6. Sources and Methodology for Diagnosed Prevalent Cases of NTM, PNTM and DNTM
• 4.7. Sources and Methodology for Diagnosed Incident and Prevalent Cases of NTM
• 4.8. Sources and Methodology for Diagnosed Incident and Prevalent Cases of PNTM
• 4.9. Sources and Methodology for Diagnosed Incident and Prevalent Cases of DNTM

5. Current Treatment Options

• 5.1. PNTM Diagnostic Paradigm
• 5.2. Treatment Paradigm
• 5.3. Current Treatment Options

6. Unmet Needs and Opportunities

• 6.1. Unmet Needs in NTM
• 6.2. New Therapeutic Options with Improved Efficacy
• 6.3. Improved Diagnostic Methods
• 6.4. Improved Clinical Trials

7. R&D Strategies

• 7.1. Trends in Clinical Trial Design in NTM
• 7.2. Trends in Deal-Making in NTM

8. Pipeline Assessment

• 8.1. NTM Pipeline Overview
• 8.2. Late-Stage Pipeline Products for NTM
• 8.3. NTM Clinical Trials (Phase II/III) Overview

9. Market Outlook

• 9.1. NTM Market Forecast
• 9.2. PNTM Market Forecast
• 9.3. DNTM Market Forecast
• 9.4. Market Drivers and Barriers

10. Appendix

• 10.1. Primary Research: KOL Information
• 10.2. Bibliography
• 10.3. About the Authors

11. Contact Us